Cite

HARVARD Citation

    Prabhu, V. et al. (2018). Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection. Clinical infectious diseases. pp. 355-362. [Online]. 
  
Back to record